Novavax and Moderna shares have started to fall. The reasons are as follows: Novavax has postponed its application to the FDA, and its quarterly report is weak, while Moderna shares are naturally correcting. Tech analysis of Novavax and Moderna shares.
All posts
The US FDA approved a drug by Biogen called Aduhelm (aducanumab) for curing Alzheimer’s. Biogen shares grew by 38.34%.
COVID-19. Unofficially, we have a vaccine. Officially, we might have it in May.
The FDA plays an integral part in analyzing companies and determining their potential. At the stage of approbation, 95% of companies work at a loss, that is why the financial analysis will show nothing.